The objective of this study is to propose and validate a new simplified model “prostascore” to help predict the outcomes of treatment-naïve patients with advanced prostate cancer.
Through SEER*Stat program, surveillance, epidemiology and end results (SEER) database was queried for eligible records spanning the period from 2010 to 2013. Multivariate analysis for the candidate prognostic factors (extent of extra-prostatic disease, PSA level and grade) was conducted through a Cox proportional model. Prostascore was then calculated for each patient. Cancer-specific and overall survival analyses according to prostascore were conducted through Kaplan-Meier analysis/log-rank testing.
A total of 8727 patients with treatment-naïve advanced prostate cancer and complete baseline data were identified in the period from 2010-2013. The following factors were associated with better cancer-specific survival (isolated regional nodal disease, lower PSA level and lower grade group) (P
Prostascore is an easy and reliable tool for predicting the outcomes of patients with treatment-naïve advanced prostate cancer. Further validation within the context of other treatment settings and population-based cohorts is recommended.
Clinical trial identification
Legal entity responsible for the study
All authors have declared no conflicts of interest.